Fight HCC^1–4 and preserve liver function⁵ with DSM-TACE

References
1. Orlacchio A et al. 2020. Radiol. Med. 125(1):98–106. 2. Mohr I et al. 2022. J. Cancer. Res. Clin. Oncol. 148(11):3163–3174. 3. Minici R et al. 2021b. Front. Pharmacol. 12:634087. 4. Minici R, et al. 2021a. Front. Pharmacol. 12:634084. 5. Ludwig JM et al. 2021. Cancers.13(20):5122. 6. Data on file: Product file of EmboCept^® S DSM 50 μm. 7. Haubold J et al. 2020. Rofo. 192(9):862–869. 8. Magle Chemoswed AB. EmboCept^® S DSM 50 μm Instruction for use. Date of information: 15.05.2020.

Intended Use / Indication For Use: EmboCept^® S DSM 50 µm suspension for injection is an adjuvant in the intra-arterial treatment of inoperable liver tumours and lung tumours in combination with cytostatic agents, the aim of which is to optimise the intra-tumoral drug accumulation. Consult the Instructions for Use for a complete listing of indications, contraindications, side effects, warnings, and precautions.

Manufacturer

Magle Chemoswed AB, Agneslundsvägen 27, SE-212 15 Malmö, Sweden Phone: +46 (0)40 38 33 00, www.maglechemoswed.com

Distributed by Sirtex Medical Pty Ltd | Shop 6, 207 Pacific Highway | St Leonards, NSW 2065 Australia | Tel: +61 2 9964 8400 | Fax: +61 2 9964 8410
Europe, Middle East & Africa | Sirtex Medical Europe GmbH | Joseph-Schumpeter-Allee 33 | 53227 Bonn | Germany | Tel: +49 228 1840 730

EmboCept^® is a registered trademark of Magle PharmaCept GmbH.
^©2023 Sirtex Medical Inc. APM-EMEA-002-10-23